This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.
StatPearls [Internet].
Show detailsContinuing Education Activity
The Food and Drug Administration (FDA)-approved indications for oral risperidone (tablets, oral solution, and M-TABs) include the treatment of schizophrenia (in adults and children aged 13 and older), bipolar I acute manic or mixed episodes as monotherapy (in adults and children aged 10 and older), bipolar I acute manic or mixed episodes adjunctive with lithium or valproate (in adults), and autism-associated irritability (in children aged 5 and older). Also, the long-acting risperidone injection has been approved for the use of schizophrenia and maintenance of bipolar disorder (as monotherapy or adjunctive to valproate or lithium) in adults. There are also many varied non-FDA-approved uses for risperidone. This activity outlines the indications, mechanism of action, administration methods, significant adverse events, contraindications, and monitoring of risperidone so providers can direct patient therapy in treating conditions for which it is indicated as part of the interprofessional team.
Objectives:
- Identify the mechanism of action for risperidone.
- Summarize the indications for initiating therapy with risperidone.
- Review the contraindications and adverse event profile for risperidone.
- Explain the importance of improving care coordination among the interprofessional team to enhance care delivery for patients who can benefit from therapy with risperidone.
Indications
Risperidone is an atypical antipsychotic medication, first approved for use in the United States by the Food and Drug Administration (FDA) in 1993. The FDA-approved indications for oral risperidone (tablets, oral solution, and meltable tablets) include the treatment of:
- Schizophrenia (in adults and children 13 and older)
- Bipolar I acute manic or mixed episodes as monotherapy (in adults and children 10 and older)
- Bipolar I acute manic or mixed episodes adjunctive with lithium or valproate (in adults)
- Autism-associated irritability (in children aged 5 and older)
The long-acting risperidone injection has received FDA approval in the treatment of schizophrenia and maintenance of bipolar disorder (as monotherapy or adjunctive to valproate or lithium) in adults. There are many varied non-FDA-approved uses for risperidone. It has been used to treat psychotic symptoms when they are present. It has also been used for borderline personality, delusional disorder, delirium, depression, brain injury, pedophilia, post-traumatic stress disorder, bipolar disorder, conduct disorder, Lesch-Nyhan, Tourette, trichotillomania, stuttering, movement disorders, and developmental disorders.[1][2] In addition to psychotic symptoms, risperidone has utility in treating aggression and agitation in patients with dementia. Risperidone has also been used to augment antidepressant therapy in the treatment of non-psychotic unipolar depression. In addition to irritability associated with autism, risperidone has also been used for social impairment, stereotypical behaviors, cognitive problems, and hyperactivity in autism.[3][4]
Mechanism of Action
All antipsychotics have some degree of antagonism at D2 receptors. First-generation antipsychotics produce antipsychotic effects at 60% to 80% D2 occupancy. Second-generation antipsychotics like risperidone exhibit their therapeutic effects through some D2 blockade but more from the blockade of serotonin receptors like 5HT2A. Second-generation antipsychotics have loose binding to D2 receptors and can quickly dissociate from the receptor, potentially accounting for the lower likelihood of causing extrapyramidal symptoms.[5]
Moreover, second-generation antipsychotics have an agonism at the 5HT1A receptor. Serotonin and norepinephrine reuptake inhibition are potential mechanisms by which risperidone is postulated to produce antidepressant effects. The improvement of positive symptoms is thought to be accomplished through the blockade of D2 receptors, specifically in the mesolimbic pathway. The ability of antipsychotics to block D2 receptors in the prefrontal cortex and nucleus accumbens is important in improving certain psychiatric symptoms. Of note, risperidone does not cause anticholinergic effects, which may benefit patients in certain populations, including the elderly with dementia.
Administration
This medication may be administered in oral form (tablets, solution, or dissolvable) or as a long-acting injection. Patients should not cut or chew the orally disintegrating tablet formulation. It is also available in injectable form.
Dosing Based on Indications Follows:
- Schizophrenia:
- For the first episode, age younger 65 years: 1 to 3 mg/day orally divided into one or two doses. Stat at 1 mg daily, then increase the dose by 0.5 mg daily every 6 to 7 days to target 2 mg daily. The maximum dose is 16 mg daily, but doses exceeding 4 mg per day are rarely more effective.
- Maintenance dosing, age younger 65 years: 1 to 4 mg/day orally divided into one or two doses. Stat at 1 to 2 mg daily, then increase the dose by 0.5 mg per day every three to seven days to target 4 mg daily. The maximum dose is 16 mg daily, but doses exceeding 4 mg per day are rarely more effective.
- Age 65 and older: 1 to 4 mg/day orally divided into 1 or 2 doses. Stat at 0.25 to 0.5 mg daily, then increase the dose by 0.5 mg per day every 6 to 7 days to target 2 mg daily. The maximum dose is 16 mg daily, but doses exceeding 4 mg per day are rarely more effective.
- Acute manic/mixed bipolar disorder:
- 1 to 6 mg/day orally divided into 1 or 2 doses. Stat at 2 to 3 mg daily, then increase the dose by 1 mg per day no more frequently than every 24 hours to target 2 mg daily. The maximum dose is 6 mg daily.
- Tourette syndrome (off-label):
- 0.2 to 3 mg daily by mouth divided once or twice daily. The maximum dose is 6 mg daily.
Renal dosing: If CrCl is less than 30, start at 0.5 mg orally twice daily; maybe increase by up to 0.5 mg twice daily until 1.5 mg twice a day, after which dosing should not increase more frequently than weekly.
Hepatic dosing: For Child-Pugh Class C, start at 0.5 mg orally twice daily; maybe increase by up to 0.5 mg twice daily until 1.5 mg twice a day, after which dosing should not increase more frequently than weekly.
Adverse Effects
Weight changes, metabolic changes, and sedation are significant concerns with risperidone. Risperidone may produce extrapyramidal symptoms (EPS), including acute dystonia, akathisia, tardive dyskinesia (TD), and Parkinsonian features. Acute/early EPS can occur at the beginning of treatment or when the dose is adjusted. Late-onset EPS (tardive dyskinesia) typically results from chronic treatment. Akathisia is a feeling of restlessness and may manifest as the patient pacing. Acute dystonia includes muscle spasms that result in abnormal postures and typically affect the head and neck. Parkinsonian features include skeletal muscle rigidity (often described as "cogwheel rigidity"), tremor, shuffling gait, and bradykinesia. Movements of the limbs, torso, neck, and head (commonly involving the tongue and lips) characterize tardive dyskinesia. This may also appear as facial grimacing or oculogyric crisis. EPS is thought to be due to D2 blockade in the nigrostriatal pathway. Since acute EPS symptoms often improve with the cessation of the medication, these side effects are a major cause of noncompliance with treatment. Although these side effects are thought to be reversible, the duration of Parkinsonian features after discontinuation of the medication can vary. Tardive dyskinesia, however, will likely persist after the medication is discontinued and may be permanent. In addition to discontinuation of the antipsychotic, pharmacologic treatments are available that may help with certain extrapyramidal symptoms.[6][7]
The antagonism of D2 receptors in the tuberoinfundibular pathway is believed to precipitate a rise in prolactin levels. The resulting hyperprolactinemia can precipitate sexual dysfunction, which has a prevalence of 45% to 80% among males and 30% to 80% among females taking this medication. Further, elevated prolactin can contribute to decreased libido, impaired arousal, and difficulty attaining orgasm. Sexual side effects may also be precipitated by risperidone's action at adrenergic (alpha 1, alpha 2) and histamine (H2) receptors. Gynecomastia, galactorrhea, and priapism have been reported in men, while galactorrhea and amenorrhea have been reported in women. It is important to note that children may be more susceptible to certain susceptible to some side effects and require careful monitoring.[8]
Serious side effects of antipsychotic medications (like risperidone) can include neuroleptic malignant syndrome (NMS). Although the pathogenesis of NMS is not clear, it is a life-threatening condition that can manifest with altered mental status, fever, "lead pipe" rigidity, and autonomic instability, including hypertension, tachypnea, and tachycardia. The use of risperidone has also been linked to a higher probability of cerebrovascular events in elderly patients with dementia, leading to an FDA warning about using this medication in the context of dementia-related psychosis. Studies have even shown an increase in all-cause mortality among the elderly with dementia who are on this medication.[9]
Contraindications
Risperidone should not be given if a known allergy/hypersensitivity to risperidone or paliperidone (a metabolite of risperidone) is present. Hallucinogen persisting perception disorder or HPPD may be a relative contraindication for risperidone because some patients treated with risperidone for their HPPD reported that panic and visual symptoms intensified.
Monitoring
Although there are no mandatory requirements for therapeutic drug monitoring with risperidone, monitoring plasma concentrations for this medication is strongly recommended by European guidelines because of data showing interdependent variability. Therapeutic monitoring can benefit from assessing compliance and identifying low drug concentrations that may be low, resulting in therapeutic failure. Also, monitoring the drug level can aid in evaluating potential drug interactions and side effects. Specific parameters should be monitored while the patient is on antipsychotics, especially in children who are more sensitive to adverse effects. When using risperidone, the clinician may derive patient benefit by monitoring serum prolactin level, hepatic functioning, metabolic functioning, thyroid functioning, weight/body mass index, height, waist circumference, blood pressure, fasting plasma glucose, insulin, fasting lipid profile, and QTc.[10][11]
Enhancing Healthcare Team Outcomes
An interprofessional healthcare team, including the primary care provider, nurse practitioner, psychiatrist, or emergency department physician who prescribes risperidone, must follow the patient. Nurses and pharmacists also play a crucial role in patient monitoring and directing the administration of the drug. The drug has many adverse effects, of which the most important are weight gain, metabolic changes, and sedation. Unlike the older antipsychotics, tardive dyskinesia is less frequently seen with the newer atypical antipsychotics like risperidone.[12][13] Nevertheless, the onus is on the healthcare team to detect any movement disorder and manage it. Countless litigations have occurred chiefly due to the lack of proper management of the adverse effects of risperidone. The optimal means to achieving the best therapeutic goal is interprofessional communication and collaboration.[14] [Level 5]
Serious side effects of antipsychotic medications (like risperidone) can include NMS. Although the pathogenesis of NMS is not clear, it is a life-threatening condition that can manifest with altered mental status, fever, "lead pipe" rigidity, and autonomic instability, including hypertension, tachypnea, and tachycardia. The use of risperidone has also been linked to a higher probability of cerebrovascular events in elderly patients with dementia, leading to an FDA warning about the use of this medication in the context of dementia-related psychosis. Studies have even shown an increase in all-cause mortality among the elderly with dementia who are on this medication.[15][12]
References
- 1.
- Boman L, De Butte M. Neurobehavioral effects of chronic low-dose risperidone administration in juvenile male rats. Behav Brain Res. 2019 May 02;363:155-160. [PubMed: 30735760]
- 2.
- Putignano D, Clavenna A, Reale L, Bonati M. The evidence-based choice for antipsychotics in children and adolescents should be guaranteed. Eur J Clin Pharmacol. 2019 Jun;75(6):769-776. [PubMed: 30729258]
- 3.
- Feiner B, Chase KA, Melbourne JK, Rosen C, Sharma RP. Risperidone effects on heterochromatin: the role of kinase signaling. Clin Exp Immunol. 2019 Apr;196(1):67-75. [PMC free article: PMC6422669] [PubMed: 30714144]
- 4.
- Fallah MS, Shaikh MR, Neupane B, Rusiecki D, Bennett TA, Beyene J. Atypical Antipsychotics for Irritability in Pediatric Autism: A Systematic Review and Network Meta-Analysis. J Child Adolesc Psychopharmacol. 2019 Apr;29(3):168-180. [PubMed: 30707602]
- 5.
- Meltzer HY, Gadaleta E. Contrasting Typical and Atypical Antipsychotic Drugs. Focus (Am Psychiatr Publ). 2021 Jan;19(1):3-13. [PMC free article: PMC8412155] [PubMed: 34483761]
- 6.
- Stogios N, Smith E, Bowden S, Tran V, Asgariroozbehani R, McIntyre WB, Remington G, Siskind D, Agarwal SM, Hahn MK. Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis. Neuropsychopharmacology. 2022 Feb;47(3):664-672. [PMC free article: PMC8782876] [PubMed: 34446830]
- 7.
- Jiwanmall SA, Gopalakrishnan R, Kuruvilla A. Tardive laryngeal dystonia with risperidone - A case report. Indian J Psychiatry. 2021 May-Jun;63(3):306-307. [PMC free article: PMC8221224] [PubMed: 34211231]
- 8.
- Trinchieri M, Trinchieri M, Perletti G, Magri V, Stamatiou K, Cai T, Montanari E, Trinchieri A. Erectile and Ejaculatory Dysfunction Associated with Use of Psychotropic Drugs: A Systematic Review. J Sex Med. 2021 Aug;18(8):1354-1363. [PubMed: 34247952]
- 9.
- Misawa F, Okumura Y, Takeuchi Y, Fujii Y, Takeuchi H. Neuroleptic malignant syndrome associated with long-acting injectable versus oral second-generation antipsychotics: Analyses based on a spontaneous reporting system database in Japan. Schizophr Res. 2021 May;231:42-46. [PubMed: 33752105]
- 10.
- Panizzutti B, Bortolasci CC, Spolding B, Kidnapillai S, Connor T, Richardson MF, Truong TTT, Liu ZSJ, Gray L, Kim JH, Dean OM, Berk M, Walder K. Biological Mechanism(s) Underpinning the Association between Antipsychotic Drugs and Weight Gain. J Clin Med. 2021 Sep 10;10(18) [PMC free article: PMC8467356] [PubMed: 34575210]
- 11.
- Guber KM, Cortes ND, Duan L. Risk of Obesity Among Children Prescribed Atypical Antipsychotics for Six Months or More. J Child Adolesc Psychopharmacol. 2022 Feb;32(1):52-60. [PubMed: 34283934]
- 12.
- Buhagiar K, Jabbar F. Association of First- vs. Second-Generation Antipsychotics with Lipid Abnormalities in Individuals with Severe Mental Illness: A Systematic Review and Meta-Analysis. Clin Drug Investig. 2019 Mar;39(3):253-273. [PubMed: 30675684]
- 13.
- Chen TR, Chen YC. Risperidone-Associated Neuroleptic Malignant Syndrome in an Inpatient With Schizophrenia, With Successful Rechallenge and 3 Year Follow-Up. Front Psychiatry. 2018;9:718. [PMC free article: PMC6305281] [PubMed: 30618887]
- 14.
- Jin B, Liu H. Comparative efficacy and safety of therapy for the behavioral and psychological symptoms of dementia: a systemic review and Bayesian network meta-analysis. J Neurol. 2019 Oct;266(10):2363-2375. [PubMed: 30666436]
- 15.
- Pozzi M, Pisano S, Marano G, Carnovale C, Bravaccio C, Rafaniello C, Capuano A, Rossi F, Rizzo R, Bernardini R, Nobile M, Molteni M, Clementi E, Biganzoli E, Radice S. Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting. J Child Adolesc Psychopharmacol. 2019 Mar;29(2):133-140. [PubMed: 30452281]
Disclosure: Shawn McNeil declares no relevant financial relationships with ineligible companies.
Disclosure: Jonathan Gibbons declares no relevant financial relationships with ineligible companies.
Disclosure: Mark Cogburn declares no relevant financial relationships with ineligible companies.
- Risperidone - StatPearlsRisperidone - StatPearls
Your browsing activity is empty.
Activity recording is turned off.
See more...